European Monitoring Centre for Drugs and Drug Addiction (EMCDDA)

The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) was established in 1993. Inaugurated in Lisbon in 1995, it is one of the EU’s decentralised agencies. The EMCDDA exists to provide the EU and its Member States with a factual overview of European drug problems and a solid evidence base to support the drugs debate. Today it offers policymakers the data they need for drawing up informed drug laws and strategies. It also helps professionals and practitioners working in the field pinpoint best practice and new areas of research.


The EMCDDA was set up to provide 'factual, objective, reliable and comparable information concerning drugs, drug addiction and their consequences'

Launch event: European Drug Report 2023


How many new drugs were detected in Europe over the last year? What are the latest trends in drug production and trafficking? What substances are causing the most concern today? Find out more when the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) launches its European Drug Report 2023: Trends and Developments in a press conference in Brussels on 16 June.

National Drug Observatories from Latin American and Caribbean countries meet in Lisbon for ‘COPOLAD week’

National Drug Observatories (NDOs) from Latin American and Caribbean (LAC) countries are gathering in Lisbon from 22–26 May for a week of activities under the COPOLAD III programme. The overarching theme of the initiative will be strengthening the technical capacity and institutional role of the NDOs. The EMCDDA is an official partner of the programme, which promotes dialogue and bi-regional cooperation on drug policy between the European Union and LAC countries.

EMCDDA Cocaine Hub

Created by


Cocaine is the hydrochloride salt produced from the leaves of the coca plant. Powder cocaine is typically snorted and less frequently injected. Crack is a smokable form of cocaine and is manufactured from cocaine hydrochloride.

Cocaine is known for its immediate effects and association with problematic patterns of drug use. 

European Drugs Summer School 2023

Lisbon, Portugal,

This two week in-person Summer School (26th of June to 7th of July 2023) prepares professionals and students to meet the complex policy challenges that face Europe and the World in the field of drugs. Teaching staff include scientific experts from the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), researchers, practitioners and policymakers.

Responding to drug-related infectious diseases: EMCDDA mini guide

Created by

Sharing drug injecting equipment increases the risk of transmitting and acquiring blood-borne infections, such as HIV and hepatitis B and C. While hepatitis C is the most prevalent blood-borne viral infection among people who inject drugs (PWID), injecting drug use remains an important mode of HIV transmission in some EU countries, and local outbreaks continue to occur.